- Home
- ALDX vs CING Comparison
ALDX vs CING Comparison
Compare ALDX & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALDX | CING |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.1M | 93.1M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALDX | CING |
|---|---|---|
| Price | $1.59 | $5.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.50 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 1.4M | 435.3K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $3.20 |
| 52 Week High | $6.18 | $11.89 |
Technical Indicators
Market Signals| Indicator | ALDX | CING |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 44.59 |
| Support Level | $1.48 | $4.94 |
| Resistance Level | $1.89 | $6.79 |
| Average True Range (ATR) | 0.10 | 0.49 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 27.38 | 47.92 |
Price Performance
Historical ComparisonAbout ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.